Loading
EB-MF-CAR-NK-01 is an experimental bispecific antibody from Beijing Biotech in phase 2 trials for mesothelioma, aimed at Mesothelin and FAP.
EB-MF-CAR-NK-01 is a bispecific antibody developed by Beijing Biotech. Its targets are Mesothelin and FAP. ClinicalTrials.gov describes the intervention as: Example investigational product: donor-derived allogeneic NK cells engineered to recognize both MSLN-positive tumour cells and FAPpositive stromal elements, manufactured under GMP. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in mesothelioma. The largest, NCT07510815, plans to enrol 36 participants with primary completion expected 2027-03-14. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Bispecific antibody directed at Mesothelin and FAP, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to Mesothelin and FAP.
1.One arm of EB-MF-CAR-NK-01 binds Mesothelin on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"EB-MF-CAR-NK-01" OR ABSTRACT:"EB-MF-CAR-NK-01" OR TITLE:"Mesothelin/FAP Dual-Target CAR-NK Cells" OR ABSTRACT:"Mesothelin/FAP Dual-Target CAR-NK Cells") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EB-MF-CAR-NK-01, not a curated reading list.
Shares Mesothelin and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.